FDA Clearance to Initiate Phase 1 Trial of the X-PACT System in Solid Tumors

DURHAM, North Carolina, August 31, 2021 — Immunolight, LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, announced today it has received FDA clearance to enter phase 1 study in patients with breast, melanoma, sarcoma and head and neck cancers.